Asco University Weekly Podcasts

Rachel Freedman, MD, MPH- Assistant Professor, Medicine, Harvard Medical School, Dana-Farber Cancer Institute presents a self-assessment question from an ASCO University course focusing on the treatment breast cancer.  AUDIO TRANSCRIPT Welcome to the self-evaluation episode of the ASCO University weekly podcast. My name is Rachel Friedman, and I'm a medical oncologist and clinical researcher in the Breast Oncology Center at Dana-Farber Cancer Institute. Today, we feature a self-evaluation question on the treatment of early stage breast cancer. We begin by reading the question stem. A 75-year-old woman with a past medical history of coronary artery disease and diabetes, with an ECOG performance status of 2, has been seen in the medical oncology office following a partial mastectomy for a 1 centimeter invasive breast cancer. The margins were clear and hormone receptors are reported as positive. The HER2/neu status is reported as negative. An Oncotype recurrence score is reported as 5. Which of the following is

Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology, Comprehensive Cancer Center at Wake Forest Baptist Health discusses identifying factors associated with prognosis and staging in a MALT lymphoma and how to identify factors predicting local failure following H Pylori eradication therapy. 

2018 Annual Meeting raised the curtain on a new session type: ASCO Voices. These noncompete session feature presentations no longer than 7 minutes each and bring a variety of perspectives to the stage to share stories on oncology, medicine, and the world. From big ideas to personal passions, ASCO Voices present stories that differ significantly from the remainder of session types available at Annual Meeting. Dr. Loehrer is director of the Indiana University Melvin and Bren Simon Cancer Center, an IU Distinguished Professor, H.H. Gregg Professor of Oncology and associate dean for cancer research at Indiana University School of Medicine.   In his ASCO Voices presentation, Dr. Loehrer shares a personal story about coping with cancer diagnosis of a close colleague and friend.  

Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

An interview with Dr. Paul Hesketh from Lahey Hospital and Medical Center on the antiemetics guideline update published in 2017. The guideline update expands the recommendations to include olanzapine and neurokinin 1 receptor antagonists. Read the full guideline at www.asco.org/supportive-care-guidelines

Rachel Freedman, MD, MPH- Assistant Professor, Medicine, Harvard Medical School, Dana-Farber Cancer Institute, presents a self-assessment question from an ASCO University course focusing on the treatment breast cancer.   

Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.

Self-Evaluation: Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology, Comprehensive Cancer Center at Wake Forest Baptist Health, presents a self-assessment question from an ASCO University course focusing on, the appropriate first line therapy for newly diagnosed primary CNS lymphoma.

An interview with Dr. Alison W. Loren of Perelman School of Medicine of the University of Pennsylvania on the ASCO guideline update which provides current recommendations about fertility preservation for adults and children with cancer. Read the full guideline at www.asco.org/survivorship-guidelines

Self-Evaluation: Apar Kishor Ganti, MD, Professor in the Department of Internal Medicine, Division of Oncology/Hematology, and Associate Director of Clinical Research at the Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, presents a self-evaluation question from an ASCO University course focusing on the treatment of an EGFR Mutation.  

Dr. Linh Alejandro, a clinical oncology pharmacist at the University of California, San Diego Health Systems discusses the approval of olaparib for germline BRCA-mutated metastatic breast cancer.

An interview with Dr. Christopher Flowers of Emory University School of Medicine on the ASCO/IDSA clinical practice guideline which provides updated recommendations on outpatient management of fever and neutropenia in patients with cancer. Read the full guideline at www.asco.org/supportive-care-guidelines

Shadia Jalal, MD, Assistant Professor of Clinical Medicine Department of Medicine Division of Hematology/Oncology Indiana University School of Medicine, presents a self-evaluation question from an ASCO University course focusing on the treatment of non-small cell lung cancers.

Dr. Rodrigo Munhoz, medical oncologist at Centro de Oncologia- Hospital Sírio-Libanês in Sao Paolo, Brazil, discusses recent advances in the adjuvant therapy for patients with high-risk melanoma

Alex Ganetsky, PharmD, BCOP, oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania in Philadelphia discusses the approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

An interview with Dr. Bryan Schneider of the University of Michigan on the ASCO clinical practice guideline to increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Read the full guideline at www.asco.org/supportive-care-guidelines 

Cindy Schwartz, MD, MPH, is an accomplished oncologist who brings 35 years of experience, passion and expertise in the areas of Hodgkin lymphoma, osteosarcoma and childhood cancer survivorship.

Dr. Carolyn Hendricks is a board certified medical oncologist specializing in breast cancer. She received her medical degree from Johns Hopkins University School of Medicine and has been in practice for more than 20 years. 

Dr. Larissa Nekhlyudov is a board-certified general internist and Medical Director of Primary Care Associates, Longwood. Dr. Nekhlyudov practiced internal medicine at Harvard Vanguard Medical Associates for over 15 years. In this episode she discusses the importance of effective communication between the primary care physician & oncologist for AYA patients diagnosed with cancer.

Dr. Suresh Ramalingam, professor of hematology and medical oncology at Emory University and Deputy Director at the Winship Cancer Institute of Emory University, presents a self-evaluation question on Clinical Trials: Informed Consent